Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000510

Drug Information
SynonymsEthyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; EINECS 250-854-5; Moricizine (USAN); CID34633; AC1L1RZ3; Oprea1_701257; Moracizine; UNII-2GT1D0TMX1; EN-313; MLS001201823; BRD-K21548250-003-03-5; Moricizine [USAN]; AC1Q35C0; LS-50419; C22H25N3O4S; DB00680; MORICIZINE; Moracizine (INN); BIDD:GT0499; ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; BAS 01947592; Moracizinum [INN-Latin]; STOCK1S-27850; Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Oprea1_682904; MolPort-001-727-947; ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Moracizinum; NCGC00016809-01; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester; NCGC00074074-03; ZINC19340795; ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Moracizina; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; BPBio1_001104; G 214; Prestwick2_001051; TimTec1_000772; AB00514710; SPBio_002931; CHEMBL1075; STK370502; HMS1536D02; AKOS001487682; AC1Q35BY; 31883-05-3; CAS-31883-05-3; SMR000059585; CBDivE_008814; Prestwick3_001051; Moracizin; AC1Q65LI; C07743; Prestwick1_001051; Prestwick0_001051; CHEBI:6997; D05077; Moracizina [INN-Spanish]; BSPBio_001002
IndicationIrregular heartbeats
[ICD9: 427   ICD10: I47-I49]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnti-Arrhythmia Agents
CAS NumberCAS 31883-05-3
PubChem Compound IDCID 34633.
PubChem Substance IDSID 9945.
SuperDrug ATC IDC01BG01
SuperDrug CAS ID031883053;
TargetSodium channel protein type 5 subunit alphaBlocker[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019753 To Reference
Ref 2From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543